|Day Low/High||5.40 / 5.93|
|52 Wk Low/High||2.11 / 9.25|
WALTHAM, Mass., Sept.
I dub Resonant and Chiasma as 'busted IPOs'.
Announces positive data from Phase 3 CHIASMA OPTIMAL trial; MYCAPSSA ® NDA submission expected by year-end 2019 with an expected six-month PDUFA review time period MPOWERED enrollment complete; topline data expected in second half 2020 Completes common...
Company to host conference call and webcast at 5:00pm ET
WALTHAM, Mass., July 26, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc.
WALTHAM, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc.
SPA-agreed trial met primary and all secondary endpoints No new or unexpected safety signals in the Mycapssa treated patients 90% of the patients treated with Mycapssa who completed the 36-week study opted to continue into the Open Label Extension Company...
Chiasma Now Estimates Approximately 130 Patients Will Be Required to Enter Run-in Phase of MPOWERED Phase 3 Clinical Trial, Versus Previous Estimate of Up to 150 Patients
Phase 3 MPOWERED Trial Surpasses 50% Patients Randomized
Anticipated release of top-line data from new OPTIMAL trial by end of 2019
Longtime Chiasma Executive Also Assumes Director Role with Chiasma, Ltd, its Israeli Subsidiary
TheStreet's biotech columnist offers his own report card on biotech stocks.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.